

# STIC Database Tracking Number: 113405

To: Sean McGarry

Location: rem/2d1/9/2c18

Art Unit: 1635

Thursday, February 05, 2004

Case Serial Number: 09/744875

From: Beverly Shears

Location: Remsen Bldg.

**RM 1A54** 

Phone: 571-272-2528

beverly.shears@uspto.gov

Sear		



U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office

# **SEARCH REQUEST FORM**

		a		•	
Requestor's Name:		Serial Number:			13
Date:	Phone:		Art Unit:		
Soarch Tonice					
Search Topic: Please write a detailed state	ement of search topic. Describe s	pecifically as possible the su	bject matter to be search	ched. Define any	
that may have a creci	ial meaning. Give examples or re sequence. You may include a cop	levent citations, authors, Key	ywords, etc., ii known.	ror sequences,	
	-				
		•			
				4	
	:				
	•				
			-		
				:	100 to 10
er tal April Territoria				÷.	
er Ma					
error s Landa de la companya	<u> </u>				_
of section	· · · · · · · · · · · · · · · · · · ·	m ridh Orit si			
		FF USE ONLY	·		
Date completed:	-05-04	Search Site	Vendors	īG	
Searcher: Beach	211	STIC CM-1	<del></del>	STN	
		Pre-S		Dialog	
Elapsed time:		Type of Search		APS	
Total time:	29	N.A. Sequence		Geninfo	2
Number of Searches:		A.A. Sequence		SDC DARC/Questel	
Number of Databases:	2	Structure Bibliographic		Other CGN	
		Біонодгарше			
500 (0 00)			_		200

	FILE	'REGISTRY' ENTERED AT 15:11:46 ON 05 FEB 2004
L.		116 SEA FILE=REGISTRY ABB=ON PLU=ON AGATTTCTAGGAATTCAAATC G
		CCTGATTTCCCCGAAATGACGGCA GTATTTCCCAGAAAAGGAAC/SQSN
Lź:		37 SEA FILE=REGISTRY ABB=ON PLU=ON L1 AND SQL=<100
	FILE	'HCAPLUS' ENTERED AT 15:13:55 ON 05 FEB 2004
T.3		16 S L2

FILE 'REGISTRY' ENTERED AT 15:11:46 ON 05 FEB 2004 116 S AGATTTCTAGGAATTCAAATC | GCCTGATTTCCCCGAAATGACGGCA | GTA L137 S L1 AND SQL=<100 L2 FILE 'HCAPLUS' ENTERED AT 15:13:55 ON 05 FEB 2004 16 S L2 L3 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN L3 ACCESSION NUMBER: 2003:571117 HCAPLUS 139:132464 DOCUMENT NUMBER: Cytokine zcytor17 ligand, polynucleotides and TITLE: antibodies for diagnosis and treatment of acute inflammatory diseases Sprecher, Cindy A.; Kuijper, Joseph L.; Dasovich, Maria M.; Grant, Francis J.; Hammond, INVENTOR(S): Angela K.; Novak, Julia E.; Gross, Jane A.; Dillon, Stacey R. Zymogenetics, Inc., USA PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 372 pp. CODEN: PIXXD2 DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

KIND I	DATE					ο.	DATE			
A2 2	20030724	•								
, AL, AM,	AT, AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,
, CR, CU,	CZ, DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,
, LR, LS,	LT, LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,
, OM, PH,	PL, PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	ТJ,
, TR, TT,	TZ, UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW,	AM,
, KG, KZ,	MD, RU,	ТJ,	TM							
, KE, LS,	MW, MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑT,	BE,
, CY, CZ,	DE, DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	IT,
, NL, PT,	SE, SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,
, GW, ML,	MR, NE,	SN,	TD,	TG						
A1 2	20031204		US	S 20	03-3	5255	4	2003	0121	
0.:			US 2002-350325P P					20020118		
		Į	US 20	002-	3753:	23P				
		į	US 20	002-	4353	15P	Ρ	2002	1219	
	A2 , AL, AM, , CR, CU, , GM, HR, , LR, LS, , OM, PH, , TR, TT, , KG, KZ, , KE, LS, , CY, CZ, , NL, PT, , GW, ML,	, AL, AM, AT, AU, CR, CU, CZ, DE, GM, HR, HU, ID, LR, LS, LT, LU, OM, PH, PL, PT, TR, TT, TZ, UA, KG, KZ, MD, RU, KE, LS, MW, MZ, CY, CZ, DE, DK, NL, PT, SE, SI, GW, ML, MR, NE, Al 20031204	A2 20030724  , AL, AM, AT, AU, AZ, , CR, CU, CZ, DE, DK, , GM, HR, HU, ID, IL, , LR, LS, LT, LU, LV, , OM, PH, PL, PT, RO, , TR, TT, TZ, UA, UG, , KG, KZ, MD, RU, TJ, , KE, LS, MW, MZ, SD, , CY, CZ, DE, DK, EE, , NL, PT, SE, SI, SK, , GW, ML, MR, NE, SN, A1 20031204	A2 20030724 WG , AL, AM, AT, AU, AZ, BA, , CR, CU, CZ, DE, DK, DM, , GM, HR, HU, ID, IL, IN, , LR, LS, LT, LU, LV, MA, , OM, PH, PL, PT, RO, RU, , TR, TT, TZ, UA, UG, UZ, , KG, KZ, MD, RU, TJ, TM , KE, LS, MW, MZ, SD, SL, , CY, CZ, DE, DK, EE, ES, , NL, PT, SE, SI, SK, TR, , GW, ML, MR, NE, SN, TD, A1 20031204 US 20	A2 20030724 WO 200 , AL, AM, AT, AU, AZ, BA, BB, , CR, CU, CZ, DE, DK, DM, DZ, , GM, HR, HU, ID, IL, IN, IS, , LR, LS, LT, LU, LV, MA, MD, , OM, PH, PL, PT, RO, RU, SC, , TR, TT, TZ, UA, UG, UZ, VC, , KG, KZ, MD, RU, TJ, TM , KE, LS, MW, MZ, SD, SL, SZ, , CY, CZ, DE, DK, EE, ES, FI, , NL, PT, SE, SI, SK, TR, BF, , GW, ML, MR, NE, SN, TD, TG A1 20031204 US 2002- US 2002-	A2 20030724 WO 2003-US , AL, AM, AT, AU, AZ, BA, BB, BG, , CR, CU, CZ, DE, DK, DM, DZ, EC, , GM, HR, HU, ID, IL, IN, IS, JP, , LR, LS, LT, LU, LV, MA, MD, MG, , OM, PH, PL, PT, RO, RU, SC, SD, , TR, TT, TZ, UA, UG, UZ, VC, VN, , KG, KZ, MD, RU, TJ, TM , KE, LS, MW, MZ, SD, SL, SZ, TZ, , CY, CZ, DE, DK, EE, ES, FI, FR, , NL, PT, SE, SI, SK, TR, BF, BJ, , GW, ML, MR, NE, SN, TD, TG  A1 20031204 US 2002-3503	A2 20030724 WO 2003-US198  , AL, AM, AT, AU, AZ, BA, BB, BG, BR, , CR, CU, CZ, DE, DK, DM, DZ, EC, EE, , GM, HR, HU, ID, IL, IN, IS, JP, KE, , LR, LS, LT, LU, LV, MA, MD, MG, MK, , OM, PH, PL, PT, RO, RU, SC, SD, SE, , TR, TT, TZ, UA, UG, UZ, VC, VN, YU, , KG, KZ, MD, RU, TJ, TM , KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, , CY, CZ, DE, DK, EE, ES, FI, FR, GB, , NL, PT, SE, SI, SK, TR, BF, BJ, CF, , GW, ML, MR, NE, SN, TD, TG  A1 20031204 US 2002-350325P US 2002-375323P	A2 20030724 WO 2003-US1984  , AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, , CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, , GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, , LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, , OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, , TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, , KG, KZ, MD, RU, TJ, TM , KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, , CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, , NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, , GW, ML, MR, NE, SN, TD, TG  A1 20031204 US 2002-350325P P US 2002-375323P P	A2 20030724 WO 2003-US1984 20036  , AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, KG, KZ, MD, RU, TJ, TM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, GW, ML, MR, NE, SN, TD, TG  A1 20031204 US 2003-352554 20034  O.:  US 2002-375323P P 20024	A2 20030724 WO 2003-US1984 20030121  , AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, , CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, , GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, , LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, , OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, , TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, , KG, KZ, MD, RU, TJ, TM , KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, , CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, , NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, , GW, ML, MR, NE, SN, TD, TG  A1 20031204 US 2002-350325P P 20020118  US 2002-375323P P 20020425

AB The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody mols. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells or hematopoietic cell progenitors in vitro and in vivo. The present invention also includes methods for producing the protein, polynucleotides and antibodies for diagnosis and treatment of acute inflammatory diseases such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, atopic dermatitis, eczema, psoriasis, endotoxemia, septicemia, toxic shock syndrome, and infectious disease.

IT 566963-54-0, 43: PN: WO03060090 SEQID: 44 claimed DNA
RL: ARU (Analytical role, unclassified); DGN (Diagnostic use); PRP
 (Properties); ANST (Analytical study); BIOL (Biological study); USES
 (Uses)

(cytokine zcytor17 ligand for hematopoietic cell expansion and for diagnosis and treatment of acute inflammatory diseases)

1

DOCUMENT TYPE:

ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN 2003:377006 HCAPLUS ACCESSION NUMBER: 138:380415 DOCUMENT NUMBER: Protein and cDNA sequences of mutant TITLE: interleukin-21 proteins and use as IL-21 antagonists Presnell, Scott R.; West, James W.; Novak, Julia INVENTOR (S): Zymogenetics, Inc., USA PATENT ASS\_GNEE(S): PCT Int. Appl., 71 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent LANGUAGE: English FAMILY ACC. NUM. COUNT: PATENT INFORMATION: APPLICATION NO. DATE PATENT NO. KIND DATE \_\_\_\_\_ \_\_\_\_ \_\_\_\_\_ WO 2002-US34502 20021028 A2 20030515 WO 2003040313 Α3 20030925 WO 2003040313 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG 20030717 20021028 US 2002-282622 A1 US 2003134390 US 2001-337586P P 20011105 PRIORITY APPLN. INFO.: The invention provides protein and cDNA sequences of two AB interleukin-21 mutants that are IL-21 antagonists that bind with specificity and exhibit an EC50 that is not detectable in receptor binding studies. These mols. have mutations in the D helix of the IL-21 mol., and can be used to inhibit the activity of IL-21 with its cognate receptor. IT 524984-78-9 RL: PRP (Properties) (unclaimed nucleotide sequence; protein and cDNA sequences of mutant interleukin-21 proteins and use as IL-21 antagonists) ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN 2003:58698 HCAPLUS ACCESSION NUMBER: 138:119583 DOCUMENT NUMBER: Method for detecting transcription TITLE: factor-protein interactions Li, Xianqiang INVENTOR(S): USA PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of SOURCE: U.S. Ser. No. 877,738. CODEN: USXXCO

Searcher : Shears 571-272-2528

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATEUT INFORMATION:

```
KIND
                           DATE
                                          APPLICATION NO.
                                                           DATE
    PATENT NO.
                     ____
                           _____
                                          _____
                                                           _____
                                                            20010905
                                          US 2001-947274
    US 2003017499
                      A1
                           20030123
                                                            20010608
                                          US 2001-877705
    US 2003008283
                      A1
                           20030109
                                          US 2001-877738
                                                            20010608
    US 2003022173
                      A1
                           20030130
                                          WO 2002-US17408 20020530
                           20021219
    WO 2002101351
                      A2
                      А3
                           20030626
    WO 2C02101351
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
        W:
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
            LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
            NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
            TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
                                                            ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
            CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
            SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
                                                        A2 20010608
                                       US 2001-877243
PRIORITY APPLN. INFO.:
                                                        A2 20010608
                                       US 2001-877403
                                                        A2 20010608
                                       US 2001-877705
                                                        A2 20010608
                                       US 2001-877738
                                                        A1 20010905
                                       US 2001-947274
```

AB A method is provided for identifying complexes between a transcription factor and another protein, the method comprising: isolating from a biol. sample transcription factor complexes based on whether the transcription factor complexes comprise a particular type of transcription factor; and identifying which of a plurality of different proteins are present in the isolated transcription factor complexes. A library of transcription factor DNA probes was contacted with nuclear exts. of untreated and PMA-treated A431 cells and then with arrays of transcription factor hybridization probes. By comparing images for each, transcription factors NF-E1 and NF-κB were found to be activated by PMA in A431 cells.

IT 488765-15-7D, biotin-labeled

RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)

(nucleotide sequence, transcription factor probe; detection of transcription factor-protein interactions)

L3 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2002:964602 HCAPLUS

DOCUMENT NUMBER:

138:34116

TITLE:

Capture of activated transcription factors by specific DNA binding and analysis of the protein

composition of the complex

INVENTOR(S):

Li, Xianqiang

PATENT ASSIGNEE(S):

Panomics, Inc., USA PCT Int. Appl., 167 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
KIND DATE
                                                APPLICATION NO. DATE
     PATENT NO.
                               -----
                        ----
      O 2002101351 A2
                                20021219
                                                WO 2002-US17408 20020530
                         A3
     20030626
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
               TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM,
          AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
               SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
               SN, TD, TG
     US 2003008283
                               20030109
                                                US 2001-877705
                                                                    20010608
                        A1
     US 2003022173
                                                US 2001-877738 20010608
                         A1
                               20030130
                        A1
                                                US 2001-947274 20010905
     US 2003017499
                               20030123
PRIORITY APPLN. INFO.:
                                             US 2001-877243 A1 20010608
                                             US 2001-877403
                                                               A1 20010608
                                             US 2001-877705
                                                               A1 20010608
                                             US 2001-877738
                                                               A1 20010608
                                             US 2001-947274
                                                               A1 20010905
     A method of identifying proteins bound to a transcription factor in
AΒ
     an activate transcription factor complex is described. The
     transcription factor is captured from a cell or nuclear extract using a
     capture probe containing a specific transcription factor binding site.
     The complexes are recovered by agarose gel electrophoresis under
     conditions that do not disrupt the complex and the proteins then
     analyzed. The method can be used to analyze nos. of transcription
     factor complexes in parallel and in several different tissues, e.g.
     comparing transcription factors in normal and neoplastic cells.
IT
     478608-20-7
     RL: PRP (Properties)
         (unclaimed nucleotide sequence; capture of activated
         transcription factors by specific DNA binding and anal. of the
         protein composition of the complex)
     ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN
                            2002:946321 HCAPLUS
ACCESSION NUMBER:
                            138:34237
DOCUMENT NUMBER:
                            Transcriptional regulator of genes involved in
TITLE:
                            the control of cell growth or cell
                            proliferation. use of said regulator as a
                            therapeutic or diagnostic agent
                            Tovey, Michael
INVENTOR(S):
PATENT ASSIGNEE(S):
                            Centre National de la Recherche Scientifique,
SOURCE:
                            PCT Int. Appl., 84 pp.
                            CODEN: PIXXD2
DOCUMENT TYPE:
                            Patent
                            English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                                                APPLICATION NO. DATE
     PATENT NO.
                         KIND
                                DATE
```

```
WO 2002-EP7064
     WO 2002098916
                             20021212
                       A2
                       АЗ
                            20031106
     WO 2002098916
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
             NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
             CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
             SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
                                         EP 2001-401476 A 20010607
PRIORITY APPLN. INFO .:
                         MARPAT 138:34237
OTHER SOURCE(S):
     Constitutive expression of the tumor suppressor genes p53 and IRF1
     (interferon regulatory factor 1) is required for the maintenance of
     the cellular growth control during genotoxic damage or abberant
     proliferation. A transcriptional regulatory element within the
     promoter region of both the p53 and IRF-1 genes which binds a pos.
     transcription factor, denoted GAAP-1 or GAAP-2 (IRF1 p53 common
     sequence binding factor). The invention relates to the
     identification and cloning of the GAAP-1 or GAAP-2 cDNA and to the
     identification of the encoded protein corresponding to the 75kDa
     product of the alternatively sliced PRDII-BF1 mRNA precursor.
     478232-52-9
     RL: PRP (Properties)
        (unclaimed sequence; transcriptional regulator of genes involved
        in the control of cell growth or cell proliferation. use of said
        regulator as a therapeutic or diagnostic agent)
     ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN
                         2002:466705 HCAPLUS
ACCESSION NUMBER:
DOCUMENT NUMBER:
                         137:52346
                         Methods of treating colitis using STAT-4
TITLE:
                         anti-sense oligonucleotides
                         Strober, Warren; Fuss, Ivan; Neurath, Markus;
INVENTOR(S):
                         Kitani, Atsushi
PATENT ASSIGNEE(S):
                         The Government of the United States of America,
                         Department of Health and Human Services, USA
                         U.S. Pat. Appl. Publ., 16 pp., Cont. of U.S. Ser. No. 535,025, abandoned.
SOURCE:
                         CODEN: USXXCO
DOCUMENT TYPE:
                         Patent
LANGUAGE:
                         English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
                                            APPLICATION NO.
     PATENT NO.
                      KIND
                             DATE
                             20020620
                                            US 2001-812028
                                                             20010319
     US 2002077308
                       Α1
                             20021112
     US 6479465
                       B2
                                         US 1999-125877P P 19990324
PRIORITY APPLN. INFO.:
                                                         B1 20000324
                                         US 2000-535025
     The present invention provides a method of treating or preventing
```

ΙT

L3

AΒ

571-272-2528

the inflammatory response of an inflammatory bowel disease in a

Searcher :

subject, comprising administering to the subject an amount of a STAT-4 antisense oligonucleotide effective in treating or preventing the

Shears

inflammatory response of the inflammatory bowel disease. 438069-80-8

RL: PRP (Properties)

(unclaimed nucleotide sequence; methods of treating colitis using STAT-4 anti-sense oligonucleotides)

ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2002:220778 HCAPLUS

DOCUMENT NUMBER:

136:261808

TITLE:

IT

New Toll-like receptors of mouse and their use in high throughput screening for CpG methylated

DNA for use as immunomodulator

INVENTOR(S):

Bauer, Stefan; Lipford, Grayson; Wagner, Hermann

Coley Pharmaceutical G.m.b.H., Germany

PATENT ASSIGNEE(S): SOURCE:

PCT Int. Appl., 194 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
KIND DATE
                                           APPLICATION NO.
                                                            DATE
     PATENT NO.
                                           _____
                      ----
                                           WO 2001-US29229
                                                            20010917
                       A2
                            20020321
    WO 2002022809
                       C2
                            20030320
    WO 2002022809
                      A3
                            20031002
    WO 2002022809
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
             NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
             TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
                                           AU 2001-91096
                                                            20010917
    AU 2001091096
                       A5
                            20020326
                                           US 2001-954987
                                                            20010917
                            20030605
    US 2003104523
                       A1
                                           EP 2001-971181
                                                            20010917
                            20031203
    EP 1366077
                       Α2
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
             PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                         Ρ
                                                            20000915
                                        US 2000-233035P
PRIORITY APPLN. INFO.:
                                        US 2001-263657P
                                                         Ρ
                                                            20010123
                                        US 2001-291726P
                                                         P
                                                            20010517
                                        US 2001-300210P
                                                         P
                                                            20010622
                                                        W
                                                            20010917
                                        WO 2001-US29229
```

The invention pertains to murine TLR9 (Toll-like receptor 9) and AΒ related Toll-like receptors and DNAs encoding them. The present invention also includes fragments and biol. functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 mols. which include murine-specific amino

acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biol. functional variants of the murine TLR7 and TLR8. Methods are included for screening for ligands of TLR7 and TLR8, as well as for inhibitors and agonists and antagonists of signaling mediated by TLR7 and TLR8. Use of the mouse TLR-9 receptor to drive NF- $\kappa$ B-dependent expression of a luciferase reporter gene in 293 cells is demonstrated.

IT 405193-24-0

RL: PRP (Properties)

(unclaimed nucleotide sequence; new Toll-like receptors of mouse and their use in high throughput screening for CpG methylated DNA for use as immunomodulator)

L3 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2002:10536 HCAPLUS

DOCUMENT NUMBER:

136:84703

TITLE:

Cytokine receptor zcytor17

INVENTOR(S):

Sprecher, Cindy A.; Presnell, Scott R.; Gao, Zeren; Whitmore, Theodore E.; Kuijper, Joseph

L.; Maurer, Mark F.

PATENT ASSIGNEE(S):

Zymogenetics, Inc., USA PCT Int. Appl., 235 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PAS	CENT 1	NO.		KIND DATE					APPLICATION NO. DATE								
				A2 20020103 A3 20030417				M				8 <b>4</b>	2001	3626				
	,,,	W:	AE, CN, GE, LC, NO,	AG, CO, GH, LK, NZ,	AL, CR, GM, LR,	AM, CU, HR, LS, PT,	AT, CZ, HU, LT, RO,	AU, DE, ID, LU, RU,	DK, IL, LV, SD,	DM, IN, MA, SE,	DZ, IS, MD, SG,	EC, JP, MG, SI,	EE, KE, MK, SK,	ES, KG, MN, SL,	BZ, FI, KP, MW, TJ, KG,	GB, KR, MX, TM,	GD, KZ, MZ, TR,	
		R₩:	RU, GH, CY,	TJ, GM, DE,	TM KE, DK,	LS, ES,	MW, FI,	MZ, FR,	SD, GB,	SL, GR,	SZ, IE,	TZ, IT,	UG, LU,	ZW, MC,	AT, NL, NE,	BE, PT,	CH, SE,	
	US EP	2003 1325 R:	0963 115 AT,	BE,	A CH,	2 DE,	2003 DK,	0709 ES,	FR,	E GB,	P 20 GR,	01-9. IT,	5225 LI,	9	2001 2001 NL,	0626	MC,	
PT, IE, SI, LT, LV, FI, JP 2004501628 T2 20040122 PRIORITY APPLN. INFO.:									J US 2 US 2 US 2	P 20 000- 000-	02-5 2142 2149	0584 82P 55P	P P	2001 2000 2000 2001	0626 0629			
AB		vel p							ides		odin	g th	еро	lype		es, a	and	

AB Novel polypeptides, polynucleotides encoding the polypeptides, and related compns. and methods are disclosed for zcytor17, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro

and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor17, are located on chromosome 5, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

ΙT 387408-25-5

RL: PRP (Properties)

(unclaimed nucleotide sequence; cytokine receptor zcytor17)

ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2001:763059 HCAPLUS

DOCUMENT NUMBER:

135:317481

TITLE:

SOURCE:

Soluble zalphall cytokine receptors

INVENTOR(S):

Sprecher, Cindy A.; Novak, Julia E.; West, James

W.; Presnell, Scott R.; Holly, Richard D.;

Nelson, Andrew J.

PATENT ASSIGNEE(S):

ZymoGenetics, Inc., USA PCT Int. Appl., 243 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PF	ATENT :	NO.		KIND DATE				APPLICATION NO. DATE									
				A2 20011018 A3 20020516													
***	W:					AT,		A7.	BA.	BB.	BG.	BR.	BY.	BZ,	CA,	CH,	
	** .					CZ,											
						ID,											
						LU,											
						RU,											
			•	uG,	UZ,	VN,	YU,	ZA,	ZW,	AM,	AZ,	BY,	KG,	KΖ,	MD,	KU,	
		ТJ,															
	RW:					MW,											
						FI,											
		TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	
		TG															
บร	2002	1376	77	A.	1	2002	0926	US 2001-825561 20010403									
EF	1303	602.		A.	2	2003	0423		E	P 20	01-9	2660	4	2001	0403		
						DK,								NL,	SE,	MC,	
						LV,											
PRIORIT	יא איף	•			/	,							P	2000	0405		
TRIOREI				• •					US 2					2000			
									WO 2				_	2001			
7 D ml		L	-14	-1	~ +h											מר מ	

- The authors disclose the preparation, structural characterization, and AΒ ligand antagonist activity of soluble homodimeric and heterodimeric receptors for zalphall. In addition, the construction of epitope-tagged and chimeric receptors and immunoadhesins are described.
- ΙT **309905-34-8,** GenBank AX047032

RL: PRP (Properties)

(unclaimed nucleotide sequence; soluble zalphall cytokine receptors)

ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN 2000:814621 HCAPLUS ACCESSION NUMBER:

> 571-272-2528 Searcher Shears

09/744875 133:359539 DOCUMENT NUMBER: Mouse cytokine receptor zcytor10 and cDNA TITLE: Presnell, Scott R.; Foster, Donald C.; Hammond, INVENTOR(S): Angela K.; Lok, Si Zymogenetics, Inc., USA PATENT ASSIGNEE(S): PCT Int. Appl., 134 pp. SOURCE: CODEN: PIXXD2 DOCUMENT TYPE: Patent English LANGUAGE: FAMILY ACC. NUM. COUNT: PATENT INFORMATION: APPLICATION NO. DATE KIND DATE PATENT NO. \_\_\_\_\_ \_\_\_\_\_\_ \_\_\_\_ \_\_\_\_\_ WO 2000-US12924 20000511 WO 2000068381 A1 20001116 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG A1 20020313 EP 2000-928962 20000511 EP 1185641 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO JP 2000-616347 JP 2002543786 20021224 20000511 T2 A 19990511 US 1999-309861 PRIORITY APPLN. INFO.:

MO 2000-US12924 W 20000511

AB Novel polypeptides, polynucleotides encoding the polypeptides, and related compns. and methods are disclosed for mouse zcytor10, a novel mouse cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells. Ligand-binding receptor polypeptides can also be used to block ligand activity. The polynucleotides encoding mouse zcytor10 can be used to identify a human ortholog. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. A partial cDNA for the rat homolog of mouse

zcytor10 was also cloned and sequenced. IT 309905-34-8, GenBank AX047032

RL: PRP (Properties)

(unclaimed nucleotide sequence; mouse cytokine receptor zcytor10 and cDNA)

REFERENCE COUNT:

5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

2000:646143 HCAPLUS 133:248680

TITLE:

Novel human cytokine zalphall ligand with therapeutic applications for eye disease

INVENTOR(S):

Novak, Julia E.; Presnell, Scott R.; Sprecher, Cindy A.; Foster, Donald C.; Holly, Richard D.; Gross, Jane A.; Johnston, Janet V.; Nelson, Andrew J.; Dillon, Stacey R.; Hammond, Angela K.

PATENT ASSIGNEE(S):

Zymogenetics, Inc., USA PCT Int. Appl., 256 pp.

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

```
APPLICATION NO.
                                                            DATE
    PATENT NO.
                     KIND
                            DATE
                                          _____
                            _____
                                          WO 2000-US6067
                                                            20000309
                     A2
                            20000914
    WO 2000053761
                      A3
                            20001221
    WO 2000053761
            AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
             CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
             VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                            20011023
                                         US 2000-522217
                                                            20000309
    US 6307024
                       B1
                                          EP 2000-916164
                                                            20000309
                       A2
                            20020102
    EP 1165791
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
             PT, IE, SI, LT, LV, FI, RO
                                           BR 2000-8772
                                                            20000309
                            20020507
    BR 2000008772
                       Α
                                           JP 2000-603382
                                                            20000309
                            20021112
                       T2
    JP 2002537839
                            20020912
                                           US 2001-923246
                                                            20010803
                       Α1
    US 2002128446
                       В2
                            20030812
    US 6605272
                                           NO 2001-4364
                                                            20010907
                       Α
                            20011109
    NO 2001004364
                                           US 2002-295723
                                                            20021115
    US 2003125524
                       Α1
                            20030703
                       В2
                            20040203
    US 6686178
PRIORITY APPLN. INFO.:
                                        US 1999-264908
                                                         A 19990309
                                        US 1999-265992
                                                         Α
                                                            19990311
                                        US 1999-142013P
                                                         Ρ
                                                            19990701
                                                         Ρ
                                        US 1999-123547P
                                                            19990309
                                                         Ρ
                                        US 1999-123904P
                                                            19990311
                                        US 2000-522217
                                                         A3 20000309
                                        WO 2000-US6067
                                                         W
                                                            20000309
```

The present invention relates to zalphall Ligand polynucleotide and AΒ polypeptide mols. The zalphall Ligand is a novel cytokine. polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo . The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.

294679-80-4

RL: PRP (Properties)

(unclaimed nucleotide sequence; novel human cytokine zalphall ligand with therapeutic applications for eye disease)

HCAPLUS COPYRIGHT 2004 ACS on STN ANSWER 12 OF 16

ACCESSION NUMBER:

2000:98716 HCAPLUS

DOCUMENT NUMBER:

132:146659

TITLE:

IT

Method using oligonucleotides for the modulation

of function of transcription factors, and

therapeutic use

INVENTOR(S):

Zuckerman, Kenneth S.; Liu, Richard Y.

University of South Florida, USA PATENT ASSIGNEE(S):

> 571-272-2528 Searcher : Shears

SOURCE:

PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

UNT: 1

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

. PA	ATENT :	NO.		KI	ND	DATE			APPLICATION NO. DATE								
															<b>-</b>		
WC	2000	2000006696			A2 20000210				M	0 19	99-U	S173	66 19990730				
WC	2000	0066	96	A.	3	2000	0316										
	W:					ΑŲ,											
		CZ,	DE,	DK,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,	GM,	HR,	ΗU,	ID,	IL,	
		IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	
		MD,	MG,	MK,	MN,	MW,	MX,	NO,	NΖ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	
		SI,	SK,	TJ,	TM,	TR,	TT,	UA,	UG,	US,	UΖ,	VN,	YU,	ZA,	ZW,	ΑM,	
						ΜĎ,										•	
	RW:					MW,											
						GB,									BF,	ВJ,	
		CF,	CG,	CI,	CM,	GΑ,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG			
AU 9953295				A.	1	2000	0221										
PRIORIT	Y APP	LN.	INFO	. :				1	US 1	998-	9469	5 P	Ρ	1998	0730		
WO 1999-US17366 W 199907												0730					

AB A method is provided for modulating the function of a transcription factor by administering an effective amount of an oligonucleotide containing optimal nucleotide binding sites for the transcription factor. A therapeutic agent having an effective amount of an oligonucleotide for modulating function of transcription factors and a pharmaceutically acceptable carrier is also provided. Also provided is a treatment of patients having illnesses in which the activation of transcription factors play a role by administering to a patient an effective amount of an oligonucleotide which competitively binds the related transcription factor.

IT 175280-54-3 257898-64-9 257898-65-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oligonucleotides for modulation of transcription factor function, and therapeutic use)

L3 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1998:501153 HCAPLUS

DOCUMENT NUMBER:

129:166205

TITLE:

Pharmaceutical composition comprising a

polynucleotide and an antigen especially for

vaccination

INVENTOR(S):

Lipford, Grayson B.; Wagner, Hermann; Heeg,

Klaus

PATENT ASSIGNEE(S):

Germany

SOURCE:

Eur. Pat. Appl., 28 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

```
19980729
                                           EP 1997-101019
                                                             19970123
     EP 855184
                       Α1
         R: DE
                                           WO 1998-EP367
                            19980730
                                                             19980123
     WO 9832462
                       A1
             AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP,
             KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
             TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
                                           AU 1998-62934
                                                             19980123
                            19980818
     AU 9862934
                       Α1
                            20000914
     AU 724325
                       B2
                            20000119
                                           EP 1998-906886
                                                             19980123
     EP 971736
                       Α1
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
             PT, IE, SI, LT, LV, FI, RO
                                            JP 1998-531592
                                                             19980123
     JP 2001508780
                      T2 20010703
                                        EP 1997-101019
                                                            19970123
PRIORITY APPLN. INFO.:
                                                        Α
                                        WO 1998-EP367
                                                          W
                                                            19980123
     The invention discloses a pharmaceutical composition comprising at least
AΒ
     one fragment of a polynucleotide and at least one antigen, especially for
     the preparation of a vaccine.
ΙŤ
     211046-24-1
     RL: PEP (Physical, engineering or chemical process); PRP
     (Properties); THU (Therapeutic use); BIOL (Biological study); PROC
     (Process); USES (Uses)
        (pharmaceutical composition comprising a polynucleotide and an antigen
        especially for vaccination)
                               THERE ARE 5 CITED REFERENCES AVAILABLE FOR
REFERENCE COUNT:
                         5
                               THIS RECORD. ALL CITATIONS AVAILABLE IN
                               THE RE FORMAT
                     HCAPLUS COPYRIGHT 2004 ACS on STN
     ANSWER 14 OF 16
                         1997:49290 HCAPLUS
ACCESSION NUMBER:
DOCUMENT NUMBER:
                         126:166477
                         Peptides derived from the IL-4 Stat
TITLE:
                         transcription factor and IL-4 receptor for use
                         as immunomodulators
                         McKnight, Steven L.; Hou, Jinzhao
INVENTOR(S):
                         Tularik, Inc., USA
PATENT ASSIGNEE(S):
                         U.S., 32 pp., Cont.-in-part of U.S. Ser. No.
SOURCE:
                         269,604, abandoned.
                         CODEN: USXXAM
DOCUMENT TYPE:
                         Patent
                         English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                      KIND
                            DATE
                                            APPLICATION NO.
                                            US 1994-276099
                                                             19940715
                            19970107
     US 5591825
                       Α
                                            AU 1995-23383
                                                             19950703
     AU 9523383
                            19960118
                       Α1
     AU 679370
                       В2
                            19970626
                                                             19950704
                                            CA 1995-2153180
     CA 2153180
                       AΑ
                            19960106
     CA 2153180
                       C
                            20010403
                                            EP 1995-304715
                                                             19950705
     EP 692488
                       Α2
                            19960117
                            19990317
                       Α3
     EP 692488
```

```
AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL,
             PT, SE
                            19960312
                                           JP 1995-169439
                                                            19950705
     JP 08067699
                       A2
                            19980903
     JP 2793977
                       В2
     US 5710266
                                           US 1997-781890
                            19980120
                                                            19970105
                       Α
PRIORITY APPLN. INFO.:
                                        US 1994-269604 B2 19940705
                                        US 1994-276099
                                                       A 19940715
    Methods for identifying peptides derived from the transcription
AB
     factor IL-4 Stat (signal transduction and activator of
     transcription) and the interleukin 4 receptor and the peptides
     themselves are described for use in the diagnosis and treatment of
     disease associated with abnormalities of interleukin 4 function.
     encoding biol. active peptides derived from these proteins may be
     used in peptide manufacture or in gene therapy. Similarly, antibodies to
     the proteins may also be of therapeutic use. The disclosed
     pharmaceutical screening methods are particularly suited to
     high-throughput screening where one or more steps are performed by a
     computer controlled electromech. robot comprising an axial rotatable
     arm. The ability of phosphotyrosine peptides derived from the IL4
     receptor to inhibit the binding of IL-4 Stat to IL4 Stat-binding
     sites of DNA in vitro is demonstrated.
ΙT
     175280-54-3
     RL: BPR (Biological process); BSU (Biological study, unclassified);
     PRP (Properties); BIOL (Biological study); PROC (Process)
        (inhibition of IL4 Stat binding to; peptides derived from IL-4
        Stat transcription factor and IL-4 receptor for use as
        immunomodulators)
    ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN
                         1996:214782 HCAPLUS
ACCESSION NUMBER:
DOCUMENT NUMBER:
                         124:281083
                         Identifying agents that bind the interleukin 4
TITLE:
                         signal transducer and transcription activator
                         for potential therapeutic use
                         Mcknight, Steven L.; Hou, Jinzhao
INVENTOR(S):
                         Tularik, Inc., USA
PATENT ASSIGNEE(S):
                         Eur. Pat. Appl., 22 pp.
SOURCE:
                         CODEN: EPXXDW
DOCUMENT TYPE:
                         Patent
LANGUAGE:
                         English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                     KIND
                           DATE
                                           APPLICATION NO.
                                                            DATE
                                           EP 1995-304715
                                                            19950705
    EP 692488
                      Α2
                            19960117
                      А3
                            19990317
    EP 692488
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL,
             PT, SE
                                           US 1994-276099
                                                            19940715
     US 5591825
                     . A
                            19970107
PRIORITY APPLN. INFO.:
                                        US 1994-269604 A 19940705
                                                        A 19940715
                                        US 1994-276099
     Methods and compns. for identifying pharmacol. agents useful in the
AΒ
     diagnosis or treatment of disease associated with the expression of a
```

Searcher : Shears 571-272-2528

gene modulated by an interleukin 4 signal transducer and activator of transcription, IL-4 Stat, are described. IL-4 Stat peptides and IL-4 receptor peptides and nucleic acids encoding such peptides find therapeutic uses. The peptides may inhibit IL-4 Stat binding to the

receptor or to their DNA binding site. The subject compns. include IL-4 Stat and IL-4 receptor proteins, portions thereof, nucleic acids encoding them, and specific antibodies. The disclosed pharmaceutical screening methods are particularly suited to high-throughput screening where one or more steps are performed by a computer controlled electromech. robot comprising an axial rotatable arm. Purification of IL-4 Stat and demonstration of inhibition by IL-4 receptor peptides is demonstrated. Receptor peptides that bind IL-4 Stat prevent formation of the active dimer form.

175280-54-3 IT

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (nucleotide sequence, IL-4 Stat-binding regulatory element; identifying agents that bind interleukin 4 signal transducer and transcription activator for potential therapeutic use)

ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2004 ACS on STN

1994:550398 HCAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER:

121:150398

TITLE:

Involvement of the transcription factor

PU.1/Spi-1 in myeloid cell-restricted expression

of an interferon-inducible gene encoding the

human high-affinity Fcy receptor

AUTHOR(S):

Perez, Christophe; Coeffier, Eliane;

Moreau-Gachelin, Francoise; Wietzerbin, Juana;

Benech, Philippe D.

CORPORATE SOURCE:

Unite 365 INSERM, Institut Curie, Paris, 75231,

Fr.

SOURCE:

Molecular and Cellular Biology (1994), 14(8),

5023-31

CODEN: MCEBD4; ISSN: 0270-7306

DOCUMENT TYPE:

Journal English

LANGUAGE: Induction by gamma interferon (IFN- $\gamma$ ) of the gene encoding the AR human high-affinity Fcγ receptor (FcγR1) in myeloid cells requires an IFN- $\gamma$  response origin (GRR) and a myeloid cell-activating transcription element (MATE). GRR and MATE interact with factors to form, resp., an IFN- $\gamma$ -activating complex (GIRE-BP), depending on the phosphorylation of the 91-kDa protein (subunit of ISGF3), and a cell-type-specific complex (MATE-BP). Although GIRE-BP is detected in cells of different origins after IFN- $\gamma$  treatment, the presence of MATE-BP was found to be restricted to B- and myeloid cell lines. Sequence anal. of a cDNA encoding a polypeptide recognizing specifically the MATE motif led to the identification of this product as the proto-oncogene PU.1/Spi-1, a transcriptional activator expressed in myeloid and B cells. Expression of this factor in nonhematopoietic cells allowed IFN- $\gamma$ -induced expression of a reporter gene under control of the GRR and MATE sequences. The presence of these motifs in other gene promoters indicates that the binding of PU.1/Spi-1 and IFN regulatory proteins to their resp. motifs could be part of a general mechanism leading to cell-type-restricted and IFN-induced gene expression.

157547-19-8, -165--78-DNA (human FcγR IgG fragment Fc ΙT receptor gene GRR element and MATE element and promoter region containing fragment)

RL: PRP (Properties)

(nucleotide sequence and function of)

# E1 THROUGH E15 ASSIGNED

FILE 'REGISTRY' ENTERED AT 15:14:30 ON 05 FEB 2004

15 SEA FILE=REGISTRY ABB=ON PLU=ON (175280-54-3/BI OR 309905-34-8/BI OR 157547-19-8/BI OR 211046-24-1/BI OR 257898-64-9/BI OR 257898-65-0/BI OR 294679-80-4/BI OR 387408-25-5/BI OR 405193-24-0/BI OR 438069-80-8/BI OR 478232-52-9/BI OR 478608-20-7/BI OR 488765-15-7/BI OR 524984-78-9/BI OR 566963-54-0/BI)

L5 15 L4 AND L1

L5 ANSWER 1 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN **566963-54-0** REGISTRY

CN 43: PN: WO03060090 SEQID: 44 claimed DNA (9CI) (CA INDEX NAME)

CI MAN

SOL 100

SEQ 1 gtacettece gtaaatecet eccetteceg gaattacace egegtattte

51 ccagaaaagg aactgtagat ttctaggaat tcaatcettg gccacgcgtc

HITS AT: 44-63

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 139:132464

L5 ANSWER 2 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN **524984-78-9** REGISTRY

CN 17: PN: WO03040313 SEQID: 17 unclaimed DNA (9CI) (CA INDEX NAME)

CI MAN

SQL 100

SEQ 1 gtacettece gtaaatecet eccetteceg gaattacaca egegtattte

======

51 ccagaaaagg aactgtagat ttctaggaat tcaatccttg gccacgcgtc

HITS AT: 44-63

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 138:380415

L5 ANSWER 3 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN **488765-15-7** REGISTRY

CN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-G-G-A-A-C) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 93: PN: US20030017499 SEQID: 93 claimed DNA

CI MAN

SQL 20

SEQ 1 gtatttcca gaaaaggaac

HITS AT: 1-20

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 138:119583

L5 ANSWER 4 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN 478608-20-7 REGISTRY

CN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 93: PN: WO02101351 SEQID: 93 unclaimed DNA

CI MAN

SQL 20

SEQ 1 gtatttccca gaaaaggaac

HITS AT: 1-20

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 138:34116

L5 ANSWER 5 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN 478232-52-9 REGISTRY

CN DNA, d(A-G-C-C-T-G-A-T-T-T-C-C-C-G-A-A-A-T-G-A-C-G-G-C-A-C-G-C-A-G-C-C-C) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 31: PN: WO02098916 PAGE: 28 unclaimed sequence

CI MAN

SQL 33

SEQ 1 agcctgattt ccccgaaatg acggcacgca gcc

HITS AT: 2-26

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 138:34237

L5 ANSWER 6 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN 438069-80-8 REGISTRY

CN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5: PN: US20020077308 SEQID: 5 unclaimed DNA

CI MAN

SQL 20

SEQ 1 gtatttccca gaaaaggaac

HITS AT: 1-20

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 137:52346

L5 ANSWER 7 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN 405193-24-0 REGISTRY

CN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 67: PN: WO0222809 SEQID: 63 unclaimed DNA

CI MAN SQL 20

SEQ 1 gtatttccca gaaaaggaac

HITS AT: 1-20

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 136:261808

L5 ANSWER 8 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN **387408-25-5** REGISTRY

CN 43: PN: WOO200721 SEQID: 43 unclaimed DNA (9CI) (CA INDEX NAME)

CI MAN SQL 100

· ·

SEQ 1 gtacetteec gtaaateect eccetteecg gaattacaec egegtattte

·51 ccagaaaagg aactgtagat ttctaggaat tcaatccttg gccacgcgtc

HITS AT: 44-63

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 136:84703

L5 ANSWER 9 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN **309905-34-8** REGISTRY

CN 37: PN: WO0068381 SEQID: 37 unclaimed DNA (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 35: PN: WO0177171 SEQID: 48 unclaimed DNA

CI MAN

SQL 100

SEQ 1 gtaccttccc gtaaatccct ccccttcccg gaattacacc cgcgtatttc

51 ccagaaaagg aactgtagat ttctaggaat tcaatccttg gccacgcgtc

HITS AT: 44-63

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

REFERENCE 1: 135:317481

REFERENCE 2: 133:359539

L5 ANSWER 10 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN

RN 294679-80-4 REGISTRY

CN 60: PN: WO0053761 SEQID: 59 unclaimed DNA (9CI) (CA INDEX NAME)

CI MAN

SQL 100

```
1 gtacettece gtaaateeet eeeetteeeg gaattacaca egegtattte
SEQ
       51 ccagaaaagg aactgtagat ttctaggaat tcaatccttg gccacgcgtc
          _____ ===
HITS AT:
          44 - 63
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
REFERENCE
           1: 133:248680
    ANSWER 11 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
L5
    257898-65-0 REGISTRY
    DNA, d(G-C-C-T-G-A-T-T-T-C-C-C-G-A-A-A-T-G-A-C-G-G-C-A),
CN
    double-stranded complementary (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
    DNA, d(T-G-C-C-G-T-C-A-T-T-T-C-G-G-G-A-A-A-T-C-A-G-G-C),
    double-stranded complementary (9CI)
OTHER NAMES:
     4: PN: W00006696 SEQID: 2 claimed DNA
CN
CI
    MAN
SQL
    25
SEQ
        1 qcctgatttc cccgaaatga cggca
          ______
HITS AT:
          1-25
           1: 132:146659
REFERENCE
    ANSWER 12 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
L5
RN
    257898-64-9 REGISTRY
    DNA, d(A-G-A-T-T-T-C-T-A-G-G-A-A-T-T-C-A-A-A-T-C), double-stranded
CN
    complementary (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
   DNA, d(G-A-T-T-T-G-A-A-T-T-C-C-T-A-G-A-A-T-C-T), double-stranded
    complementary (9CI)
OTHER NAMES:
    3: PN: WO0006696 SEQID: 1 claimed DNA
CN
CI
    MAN
SQL
    21
SEQ
        1 agatttctag gaattcaaat c
          HITS AT:
          1 - 21
REFERENCE
          1: 132:146659
    ANSWER 13 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN
L5
    211046-24-1 REGISTRY
RN
                                                          (CA INDEX
    DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C) (9CI)
CN
    NAME)
CI
    MAN -
SQL
    20
        1 gtatttccca gaaaaggaac
          HITS AT:
          1 - 20
**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
```

REFERENCE 1: 129:166205 ANSWER 14 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN  $L_5$ 175280-54-3 REGISTRY RN DNA, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C), double-stranded CN complementary (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES: Deoxyribonucleic acid, d(G-T-A-T-T-T-C-C-C-A-G-A-A-A-A-G-G-A-A-C), CN double-stranded complementary DNA, d(G-T-T-C-C-T-T-T-T-C-T-G-G-G-A-A-A-T-A-C), double-stranded CN complementary (9CI) OTHER NAMES: 5: PN: WOOOO6696 SEQID: 3 claimed DNA CI MAN SQL 20 1 gtatttccca gaaaaggaac SEO \_\_\_\_\_ HITS AT: 1-20 \*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\* 132:146659 REFERENCE 1: 126:166477 REFERENCE 2: 124:281083 REFERENCE 3: ANSWER 15 OF 15 REGISTRY COPYRIGHT 2004 ACS on STN L5**157547-19-8** REGISTRY RN DNA (human immunoglobulin G receptor gene promoter region GRR CN element plus MATE element-containing fragment) (9CI) (CA INDEX NAME) OTHER CA INDEX NAMES: Deoxyribonucleic acid (human immunoglobulin G receptor gene promoter region GRR element plus MATE element-containing fragment) OTHER NAMES: DNA (human FcyR IqG fragment Fc receptor gene GRR element and CN MATE element and -165--78 promoter region containing fragment) CI MAN 88 SOL 1 gtttcaagga tttgagatgt atttcccaga aaaggaacat gatgaaaatg SEQ \_\_ \_\_\_\_\_ 51 gtcagaaaag gcaatttcct teetettte taatttgg 19-38 HITS AT: 1: 121:150398 REFERENCE

FILE 'HOME' ENTERED AT 15:15:00 ON 05 FEB 2004